Radiotherapie von Lungenkarzinomen – Indikationsspektrum hat sich in den letzten Jahren deutlich erweitert

Die Strahlentherapie ist bislang zumeist in der postoperativen Situation oder für Patienten mit fortgeschrittenen Tumoren angewandt worden. Moderne Hochpräzisionstechniken ermöglichen heute jedoch eine Ausweitung der Indikationen auch auf frühe Stadien des nicht kleinzelligen Lungenkarzinoms. Mithilfe der extrakraniellen stereotaktischen Radiotherapie, der intensitätsmodulierten Radiotherapie oder einer bildgeführten Strahlentherapie lassen sich hohe Strahlendosen applizieren, wobei gleichzeitig das umgebende normale Gewebe geschont wird. Dieser Artikel gibt einen Überblick zu den aktuellen und künftigen Therapiealgorithmen in der Radioonkologie

For the last decades radiotherapy was delivered postoperative or in advanced stage lung cancer. High precision radiotherapy techniques opened a window for curative treatment in early NSCLC. Techniques like stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT) or image guided radiotherapy (IGRT) deliver high doses to the tumor by sparing normal tissue. This article describes the current therapy algorithms in radiooncology with respect to future strategies.

Key words

lung cancer - IMRT - IGRT - SBRT - chemoradiation

• Literatur

• 1 Büther F, Ernst I, Dawood M et al. Detection of respiratory tumour motion using intrinsic list mode-driven gating in positron emission tomography. Eur J Nucl Med Mol Imaging 2010; 37: 2315-2327
• 2 Ernst I, Büther F, Dawood M et al. First results from list mode based target delineation in high precision radiotherapy. Radiother Oncol 2010; 94 (Suppl. 01)
• 3 Halperin EC, Perez CA, Brady LW. Perez and Brady's Principles and Practice of Radiation Oncology (4^th ed.). Baltimore: Lippincott Williams & Wilkins; 2007: 1076-1108
• 4 Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24: 2998-3006
• 5 Pöttgen C, Eberhardt W, Bildat S et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol 2002; 13: 403-411
• 6 Hehr T, Friedel G, Steger V et al. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected stage III non-small-cell lung cancer: long-term results of a trimodality phase II protocol. Int J Radiat Oncol Biol Phys 2010; 76: 1376-1381
• 7 Curran W, Scott C, Langer C. Long term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable NSCLC. Proc Am Soc Clin Oncol 2003; 61-61
• 8 Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique – Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-5917
• 9 Boda-Heggemann J, Lohr F, Wenz F et al. kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 2011; 187: 284-291
• 10 Dosoretz DE, Galmarini D, Rubenstein JH et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 1993; 27: 507-516
• 11 Levendag PD, Lagerwaard FJ, dePan C et al. High-dose, high-precision treatment options for boosting cancer of the nasopharynx. Radiother Oncol 2002; 63: 67-74
• 12 Belderbos S, De Jaeger K, Heemsbergen WD et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003; 66: 119-126
• 13 Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracrancial tumors using an accelerator. Clinical experience of first thirty-one patients. Acta Oncolog 1995; 34: 861-870
• 14 Uematsu M, Shioda A, Tahara K et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998; 82: 1062-1070
• 15 Wulf J, Hädinger U, Oppitz U et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001; 177: 645-656
• 16 Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005; 77: 83-87
• 17 Nagata Y, Negoro Y, Aoki T et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002; 52: 1041-1046
• 18 Hof H, Herfarth KK, Münter M et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003; 56: 335-341
• 19 Timmermann B, Kortmann RD, Kühl J et al. Role of raditherapy in anaplastic ependymoma in children under age of 3 years results of the prospective German brain tumor trials HIT-SKK 87 and 92. Radiother Oncol 2005; 278-285
• 20 Ernst I, Lücking PS, Eickmeyer F et al. Extrakranielle stereotaktische Radiotherapie (ESRT) – eine Übersicht unter besonderer Berücksichtigung von ESRT und LITT in der Behandlung von Lebermetastasen. Zentralbl Gynakol 2006; 128: 71-75
• 21 Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000; 18: 106-115
• 22 Naruke T, Tsuchiva R, Kondo H, Assamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification; the Japanese experience. Ann Thoracic Surg 2001; 71: 1759-1764
• 23 Shimokata K. Jap J Lung Cancer 2007; 47: 299-311
• 24 Onishi H. J Thor Oncol 2007; 2 (Suppl. 03) 94-100
• 25 Palma D, Lagerwaard F, Rodrigues G et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review. Int J Radiat Oncol Biol Phys [Epub ahead of print] 01.06.2011;
• 26 Ernst I, Kraxner P, Moustakis C et al. Palliative Radiatio mittels ESRT zur Linderung ausgeprägter Dyspnoe bei Patienten mit fortgeschrittenem Bronchialkarzinom. DEGRO – OEGRO 2008; Strahlenther Onkol 2008; 184 (Suppl. 01)
• 27 Iwata H, Murakami M, Demizu Y et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer 2010; 116: 2476-2485
• 28 Xia B, Chen GY, Cai XW et al. The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. Radiat Oncol 2011; 6: 50-50
• 29 Goeckenjan G, Sitter H, Thomas M et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010; 64 (Suppl. 02)
• 30 Pöttgen C, Eberhardt W, Grannass A et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 2007; 25: 4987-4992
• 31 Blanchard P, Le Pechoux C. Prophylactic cranial irradiation in lung cancer. Curr Opin Oncol 2010; 22: 94-101